Allakos

About:

Allakos is a biotechnology company developing therapeutic antibodies targeting allergy, inflammatory and proliferative diseases.

Website: https://www.allakos.com

Top Investors: New Enterprise Associates, RTW Investments, Frazier Life Sciences, Samsara BioCapital, Deep Track Capital

Description:

Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatory responses. Allakos was founded in 2012 and is headquartered in San Carlos, California.

Total Funding Amount:

$312M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Carlos, California, United States

Founded Date:

2012-01-01

Contact Email:

info(AT)allakos.com

Founders:

Christopher Bebbington, Nenad Tomasevic

Number of Employees:

101-250

Last Funding Date:

2022-09-19

IPO Status:

Public

© 2025 bioDAO.ai